We would love to hear your thoughts about our site and services, please take our survey here.
In the second part of his presentation, Dr Johnson will speak about an innovative class of Affimers that captures antibodies but only when the antibodies are bound to their own targets. This offers a route to improving an important type of diagnostic test to have a more specific and clearer result. The commercial potential for this class of Affimer is significant.
Alastair Smith - “This is another important milestone for Avacta, because it further validates the Affimer technology and our licensing business model. We have built a pipeline of evaluations and collaborations, such as this one with New England Biolabs, to deliver numerous license agreements to commercialise Affimer-based products. Collectively, these royalty bearing licenses will underpin the future high margin revenue from Affimer reagents.”
Hope he/she doesn’t mind me sharing..... I was at the Proactive investor meeting last night and was impressed by the presentation. I was already a shareholder as a result of the recent fund raising but hadn't really looked into the technology as much as I should have done. There are various aspects of the affymer platform which are advantageous. For example the fact that the structure gets around the antibody IP mean that this technology can be used in a variety of beneficial ways. In addition the fact that the reagents used in the diagnostic area are plant based means it is distinctly separate from the therapeutic products. Plus the company is clearly focused on getting deals in the short term. The CEO said a diagnostics deal is imminent and others will follow. And the company is funded into 2020 and that doesn't include any deals in the interim. The key time will be when they get to the first in human studies which will be Q1 next year with the PDL1-LAGS bispecific. Yes I have bought some more this morning via spreadbet.... Nobby
Hi Mostly, all good and news as expected. This company is finally going places, so much in the pipeline in the very near future. I’m expecting many multiples on today’s price within 24 months. Have a listen to the recent CEO interview.
Avacta Group's Bach BioSciences deal 'an exciting step' - Capital Network analyst - http://www.proactiveinvestors.co.uk/companies/amp/media_files/9995?__twitter_impression=true